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TABLE 1. Postoperative transmitral gradient and mitral complex parameters
Posterior PMS Anterior PMS P value
E (m/s) 1.6  0.2 1.2  0.2 .004
Peak pressure gradient (mm Hg) 10.0  2.6 5.8  1.9 .004
Papillary muscle angle (anterior) 47  10 55  8 .131
Papillary muscle angle (posterior) 106  10 93  12 .042
Left ventricular inflow angle 60  6 78  9 <.001
Stroke volume index (mL/m2) 28  5 37  11 .054
PMS, Papillary muscle suspension to annuloplasty ring. Values  standard deviation.
Letters to the Editorapparatus during exertion and indicated
that not only MAP but also further mi-
tral tethering causes functional MS.
This study has a considerable impact
on the surgical strategy for IMR in the
future.
In 2003, we developed mitral com-
plex reconstruction, which consists of
MAP, papillary muscle (PM) approxi-
mation,3 and (since 2005) suspension
(PMS),4 and have aggressively adopted
this procedure for patients with heart
failure and functional mitral regurgita-
tion. In PMS, we place a subval-
vular expanded polytetrafluoroethylene
(ePTFE) suture between the site of the
chordal attachment of the approximated
PM and the mitral annulus. We consid-
ered that posterior PMS, in which
ePTFE suture is sewn to the middle of
the posterior annuloplasty ring, causes
further anterior mitral valve tethering
in diastole. Therefore, we recently
changed from posterior to anterior
PMS, in which ePTFE suture is sewn
to the middle of the anterior annulo-
plasty ring. Table 1 shows the postoper-
ative transmitral gradients and mitral
complex parameters (n ¼ 8, for each
group). The left ventricular (LV) inflow
line was measured using Doppler color
flow mapping at the time of maximal
early diastolic rapid filling by an apical
long-axis view. The angle between this
line and the annulus was measured as
the LV inflow angle. PM angles were
also measured with the line between
the tip of the PMand the septal side (an-
terior) or posterior side (posterior) of
mitral annulus in end diastole. LV in-
flow angle was significantly larger and
posterior PM angle was significantly
smaller in the anterior PMS group. Mi-
tral peak pressure gradient was signifi-
cantly smaller in the anterior PMS
group (5.8  1.9 mm Hg) than in the
posterior PMS group (10.0  2.6 mm
Hg), which is comparative to that of
Kubota and colleagues’ report1
(10.6  6.2 mm Hg).
Although our parameters are differ-
ent from those of Kubota and col-
leagues’ report,1 LV inflow and PM
angles would correspond well to the252 The Journal of Thoracic and Cparameters determining mitral valve
tethering in their report. We consider
that mitral valve tethering during dias-
tole could be ameliorated by anterior
PMS, which can relocate the PM to-
ward the septal side of the ventricle
but not the posterior side. Langer and
colleagues5 recently reported a better
mitral regurgitation recurrence rate
with a subvalvular procedure termed
‘‘RINGþ STRING.’’ We should fur-
ther examine the relationship between
these subvalvular procedures and
functional MS after operation.
Yasushige Shingu, MD, PhD
Yoshiro Matsui, MD, PhD
Department of Cardiovascular
Surgery
Hokkaido University Hospital
Sapporo, Japan
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We appreciate the comments by Drs
Shingu and Matsui. Our investigation
showed that functional mitral stenosis
(MS) after surgical annuloplasty for is-
chemic mitral regurgitation (MR) is
not rare.1,2 Mechanistically, diastolic
leaflet tethering to restrict its opening
in the presence of surgical reduction
of annular size causes this functional
MS.2 The degree of functional MS is
proportional to the degree of recurrent
MR after the surgery, and both are
closely related to subvalvular tether-
ing. Therefore, functional MS and re-
current MR can be interpreted as
a single pathophysiology, presenting
in diastole and systole as a different
form. Procedures to reduce subvalvu-
lar tethering seem reasonable to ad-
dress functionalMS and recurrentMR.
In this context, the data presented by
Drs Shingu and Matsui are interesting.
They compared 2 surgical techniques
to address subvalvular tethering by
shortening the distance between both
sides of the papillary muscle (PM)
tips and mitral annulus: technique
number 1 to displace the PM tips to-
ward the posterior mitral annulus and
technique number 2 to shift the PM
tips toward the anterior annulus. The
degree of functional MS is signifi-
cantly less with PM displacement pro-
cedure toward the anterior annulus.
The favorable results by PM displace-
ment toward the anterior mitral annu-
lus seem reasonable, because the
procedure is likely to reduce tethering
in both systole and diastole, whereas
PM displacement toward the posterior
mitral annulus may impair the systolic
closure of posterior leaflet and dia-
stolic opening of the anterior leaflet.
Letters to the EditorThe data by Drs Shingu and Matsui
suggest the utility and need for proce-
dures to address subvalvular tethering
in patients with ischemic MR. Cur-
rently reported surgical procedures to
address subvalvular tethering are
conceptually reasonable and heteroge-
nous.3-5 A tailored and heterogeneous
approach based on preoperative 3-
dimensional evaluation of mitral valve
geometry seems necessary to address
patients’ variability. Standardization is
also necessary to perform subvalvular
procedures in many institutions. This
bidirectional improvement in therapeu-
tic approach is required to achieve a fa-
vorable outcome in affected patients.
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CYCLOPHOSPHAMIDE ON
MYOCARDIAL ISCHEMIA/
REPERFUSION INJURY IN RATS
To the Editor:
Wang and associates1 have recently
published a very interesting and in-
novative origin of thought in which
investigators have demonstrated the
protective role of cyclophosphamide
against myocardial ischemia/reperfu-
sion injury in rats. In this study, cyclo-
phosphamide showed a favorable
effect on myocardial function in vari-
ous parameters, which included im-
provement in left ventricular systolic
pressure, left ventricular end-diastolic
pressure, and maximum rate of rise or
fall of left ventricular pressure. Apart
from this, infarct size was reduced,
alongwith improvement in histopatho-
logic damage score, and plasma high-
sensitivity C-reactive protein concen-
tration, which is an inflammatory
marker, was reduced significantly.
However, we would like to highlight
some of the points regarding this study
1. The study showed that cyclophos-
phamide decreased the C-reactive
protein levels significantly, but it
is not the proposed specific mecha-
nism of action alone to have
anti-inflammatory action. Other
markers of inflammation, such as
Cox inhibition, should also have
been evaluated before making the
final conclusion.
2. In this study, pretreatment with
cyclophosphamide or saline was
given before inducing ischemia/re-
perfusion. Thus, in this study de-
sign, investigators should have
evaluated whether the drug cyclo-
phosphamide or saline had any
beneficial or detrimental effect be-
fore proceeding for ischemia and
reperfusion or sham surgery.
3. The cardioprotective role of cyclo-
phosphamide could have been
evaluated on creatine kinase, myo-
cardial band of creatine kinase,
and tropinin I, which are the myo-
cardial injury markers.2,3of Thoracic and Cardiovascular Surge4. Various studies have evaluated the
role of cytokines, which include
interleukins 6 and 8, interferon-
gamma, and tumor necrosis factor-
a, which are upregulated after ische-
mia/reperfusion injury.4,5 In this
present study, too, the expression
of these cytokines, which are medi-
ators of inflammation, could have
been evaluated in comparison with
saline or cyclophosphamide.
The present study provides useful
information for more effective and
targeted treatment for patients with
ischemic heart disease, but the afore-
mentioned points should be discussed
for future therapeutic implication and
reconfirmation in clinical studies.
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